申请人:Bayer Aktiengesellschaft
公开号:US03959292A1
公开(公告)日:1976-05-25
4,5-Dihydropyridines bearing an N,N-disubstituted amino group in the 2-position, carbonyl functions in the 3- and 5-positions and being optionally substituted in the 6-position by lower alkyl or phenyl and, in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, are antihypertensive agents and coronary vessel dilators. The compounds, of which 2-pyrrolidino-6-methyl-4-(3-nitrophenyl)-4,5-dihydropyridine-3,5-dicarboxy lic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a substituted 3,3-diaminoacrylate.
2-位带有 N,N-二取代氨基基团,3-位和5-位带有羰基功能团的4,5-二氢吡啶,可选择性地在6-位被低碳烷基或苯基取代,在4-位被低碳烷基、苯基、取代苯基或杂环基取代。这些化合物是降压药和冠状血管扩张剂。其中2-吡咯烷基-6-甲基-4-(3-硝基苯基)-4,5-二氢吡啶-3,5-二羧酸3,5-二乙酯是一种代表性的化合物,通过酰乙酸乙酯和取代的3,3-二氨基丙烯酸酯的缩合反应制备。